Table 2.

Evaluation of treatment response for 10 patients with neuroblastoma

Tumor lesion		Case 1	Case 2	Case 3	Case 4	Case 5	Case 6	Case 7	Case 8	Case 9	Case10
Primary tumor site	Initial diagnosis	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive
	After induction therapy	CR	CR	CR	PR	CR	CR	CR	PR	PD	PR
	First progression or recurrence	CR*	CR	CR	CR	PD	CR	CR	PD	PD	PR
Lung	Initial diagnosis	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive
	After induction therapy	CR	PD	SD	SD	SD	PR	PR	PR	PD	PD
	First progression or recurrence	CR	PD	SD	PR	PR	CR	CR	PD	PD	PD
Bone marrow	Initial diagnosis	Positive	Positive	Negative	Negative	Positive	Positive	Positive	Positive	Negative	Negative
	After induction therapy	CR	MD	Negative	Negative	CR	MD	MD	MD	Negative	Negative
	First progression or recurrence	CR	PD	Negative	Negative	MD	MD	MD	MD	Negative	Negative
Bone	Initial diagnosis	Positive	Positive	Negative	Negative	Positive	Positive	Positive	Positive	Negative	Negative
	First progression or recurrence	CR	PD	Negative	Negative	PD	Unknown	PD	PD	Negative	Negative
Distant lymph node	Initial diagnosis	Negative	Positive	Positive	Negative	Negative	Negative	Positive	Positive	Negative	Positive
	After induction therapy	Negative	PR	SD	Negative	Negative	Negative	SD	PR	Negative	PR
	First progression or recurrence	Negative	PD	PR	Negative	Negative	Negative	PD	SD	Negative	PR
Liver	Initial diagnosis	Negative	Positive	Positive	Negative	Negative	Negative	Positive	Positive	Positive	Negative
	After induction therapy	Negative	CR	SD	Negative	Negative	Negative	SD	PR	PD	Negative
	First progression or recurrence	Negative	PD	PD	PD	Negative	Negative	CR	SD	PD	Negative

*Case 1 has not experienced a recurrence or progression of the disease.

CR, complete response; MD, minimal disease; PD, progressive disease; PR, partial response; SD, stable disease.